We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Pacific Biosciences Acquires Single Molecule Sequencing Technology from LI-COR Biosciences
News

Pacific Biosciences Acquires Single Molecule Sequencing Technology from LI-COR Biosciences

Pacific Biosciences Acquires Single Molecule Sequencing Technology from LI-COR Biosciences
News

Pacific Biosciences Acquires Single Molecule Sequencing Technology from LI-COR Biosciences

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Pacific Biosciences Acquires Single Molecule Sequencing Technology from LI-COR Biosciences"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Pacific Biosciences announced that it has acquired "sequencing by incorporation" technology from LI-COR Biosciences of Lincoln Nebraska. Sequencing by incorporation generally identifies nucleotides in a DNA sequence based upon synthesis of a complementary DNA strand.

The technology acquired from LI-COR broadens Pacific Biosciences' existing intellectual property related to the SMRT™, single molecule real time, sequencing method. Developed by Pacific Biosciences, SMRT technology is unique in the field of DNA Sequencing and offers the ultimate combination of speed, long reads, and low costs.

Included in the acquisition is a significant portfolio of key intellectual property developed under LI-COR's single molecule sequencing program, including a number of issued US and foreign patents as well as a number of pending US applications.

LI-COR retained rights to its intellectual property for the sequencing enzymes that were designed for sequencing by polymerase synthesis, and LI-COR has an active program to out-license its enzymes. The acquisition also includes ongoing opportunities to collaborate with the LI-COR scientists on its sequencing enzymes.

Advertisement